Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PGNX > SEC Filings for PGNX > Form 8-K on 9-Dec-2013All Recent SEC Filings




Other Events, Financial Statements and Exhibits

Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) today announced that it has completed enrollment of chemotherapy experienced patients in its Phase II trial to assess the anti-tumor activity and tolerability of its antibody drug conjugate candidate, PSMA ADC, in patients with metastatic castrate resistant prostate cancer. The company has also initiated treatment in an additional trial cohort, now enrolling, of chemotherapy naive patients who have progressed on hormonal therapies.

Progenics separately announced that findings from a Phase I study of its Molecular Insight subsidiary's imaging agent candidate, 1404, were presented today at the 14th Annual Meeting of the Society of Urologic Oncology being held in Rockville, Maryland.

Copies of the company's press releases are included in this Report as Exhibits 99.1 and 2, and the information contained therein is incorporated into this Item 8.01 by this reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated December 6, 2013.

99.2 Press Release dated December 6, 2013.

  Add PGNX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PGNX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.